NCT02296684View on ClinicalTrials.gov

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 25, 2015

Primary Completion Date

April 5, 2022

Study Completion Date

December 31, 2025

Conditions
Cancer of Head and NeckHead and Neck CancerNeoplasms, Head and NeckCarcinoma, Squamous Cell of Head and NeckSquamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma, Head and Neck
Interventions
BIOLOGICAL

MK-3475 (neoadjuvant)

PROCEDURE

Surgery

Standard of care

RADIATION

Intensity modulated radiation therapy

Recommended, standard of care

RADIATION

Image-guided radiation therapy

Recommended, standard of care

DRUG

Cisplatin

Standard of care

BIOLOGICAL

MK-3475 (adjuvant)

PROCEDURE

Peripheral blood

-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

63110

Washington University School of Medicine, St Louis

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Washington University School of Medicine

OTHER